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Abstract: Plant extracts are complex matrices and, although crude extracts are widely in use, 
purified compounds are pivotal in drug discovery. This study describes the application of 
automated preparative-HPLC combined with a rapid off-line bacterial bioassay, using 
reduction of a tetrazolium salt as an indicator of bacterial metabolism. This approach 
enabled the identification of fractions from Dodonaea viscosa that were active against 
Staphylococcus aureus and Escherichia coli, which, ultimately, resulted in the identification 
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of a clerodane type diterpenoid, 6β-hydroxy-15,16-epoxy-5β, 8β, 9β, 10α-cleroda-3, 13(16), 
14-trien-18-oic acid, showing bacteriostatic activity (minimum inhibitory concentration 
(MIC) = 64–128 µg/mL) against test bacteria. To the best of our knowledge, this is the first 
report on antibacterial activity of this metabolite from D. viscosa. 
Keywords: Dodonaea viscosa; preparative HPLC; XTT assay; clerodane diterpenoid 
 
1. Introduction 
The global presence and rise of antibiotic resistant pathogens and decline in antibiotic drug 
discovery programs by pharmaceutical companies are prompting the scientific community to search 
for new and also re-examine old sources of bioactive chemicals in order to identify potential drugs [1]. 
Medicinal plants are an area under focus since their secondary metabolites encompass a significant 
number of drugs used in current therapeutics and there is no doubt in their potential as the source of 
new medicines [2]. 
Dodonaea viscosa (L.) Jaeq. is an evergreen shrub in Pakistan and is locally known as Ghawraskay 
(Pushto). It is traditionally used to treat a wide range of medical conditions from colds to malaria [3,4], 
and crude extracts have been shown to be active against bacterial, viral, fungal and protozoal  
pathogens [5–7]. However, despite numerous phytochemical investigations, only a single compound, 
hautriwaic acid, with moderate antibacterial activity has been characterized [8]. 
Isolation and characterization of bioactive molecules from crude plant extracts or fractioned extracts 
are challenging tasks. This is mainly due to the presence of a large number of metabolites with close 
physicochemical properties with often complementing bioactivities. However, in order to standardize 
them, their separation is necessary. Chromatographic methods have revolutionized the separation of 
such complex mixtures and the combination of chromatography with spectroscopic and spectrophotometric 
methods such as mass spectroscopy, UV, NMR etc. has further eased the task. In this context, 
preparative HPLC has shown to be an essential tool for producing high quality natural products and if 
strict quality control is undertaken, the approach ensures reliable screening results [9,10]. 
Currently, cell viability assays make use of one of several tetrazolium salts in a microplate format. 
Metabolically active cells reduce the tetrazolium salts and result in coloured formazan products that 
can be simply read by a plate reader, thus offering rapid records on the metabolic status of the cell [11]. 
XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) is a tetrazolium salt 
that does not require the additional solubilisation step as required in the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay and yields a reduced formazan product that is water 
soluble [11]. The XTT assay is exploited in determination of antimicrobial activity of simple plant 
extracts [12,13]. This study describes the combination of automated preparative HPLC in combination 
with an XTT bioassay for rapid identification of antibacterial fractions and derived active compound 
from D. viscosa. 
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2. Results and Discussion 
2.1. Fractionation of Plant Material 
Liquid-liquid fractionation of the crude aqueous extract of D. viscosa resulted in 75 g of an  
n-hexane fraction (H), 70 g of a dichloromethane fraction (D), 92 g of an ethyl acetate fraction (E),  
81 g of an n-butanol fraction (B) that spontaneously solidified, and 126 g of thick suspension of an 
aqueous fraction (A). 
2.2. Preliminary Antibacterial Screening 
Extracts of D. viscosa derived from hexane and ethyl acetate were active against E. coli (the National 
Collection of Industrial, Marine and Food Bacteria (NCIMB) 8797) and S. aureus (NCIMB 6571), 
whereas the butanol extract was only active against S. aureus (Table 1). Previous studies on D. viscosa 
fractions showed bacteriostatic activity against Gram positive bacteria, but not Gram negative such as 
E. coli [5,6]; our results indicated that the hexane and ethyl acetate fractions inhibited E. coli.  
These opposite findings may be due to differences in the plant material, extraction protocols and test 
strains used. As there is growing interest in the generation of libraries of simplified extracts prior to 
screening [9,10], our approach aimed to select those extracts which exhibited antibacterial activity and 
use preparative HPLC with the XTT assay for rapid screening of a large number of fractions. 
Table 1. Antibacterial activity (average zones of inhibitions in mm ± SD) of crude solvent 
fractions determined by disk diffusion assay. 
D. viscosa Test Bacteria 
Fraction E. coli (NCIMB 8797) S. aureus (NCIMB 6571) 
Hexane (H) 12.5 ± 0.5 11.4 ± 0.5 
Dichloromethane (D) 0.0 0.0 
Ethyl acetate (E) 9.7 ± 0.3 9.0 ± 0.2 
Butanol (B) 0.0 10.0 ± 0.2 
Aqueous (A) 0.0 0.0 
Ciprofloxacin 31.0 ± 0.5  – 
Clarithromycin – 28.6 ± 0.5 
Ciprofloxacin (10 µg/disk); Clarithromycin (15 µg/disk) (positive controls); Methanol (negative control). 
2.3. Optimization of XTT (2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5- 
carboxanilide) Bioassay 
Ciprofloxacin (50 µg/mL) and clarithromycin (25 µg/mL) inhibited the test strains of E. coli and  
S. aureus, respectively, after 24 h incubation in the XTT assay, as shown by the decreased absorbance. 
The effect of ciprofloxacin on E. coli was evident after 2 h incubation, with absorbance in the treated 
cells at 0.042 compared to the solvent control at 0.098. However, 24 h incubation was necessary to 
obtain an evident result on the effect of clarithromycin on S. aureus; therefore 24 h incubation was 
selected as incubation period. 
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2.4. Generic Preparative HPLC-XTT Bioassay 
The use of solvents such as methanol and water along with a volume-based fractionation strategy  
was necessary as the active component(s) may not contain a chromophore. For the extract, a total of  
52 primary fractions were collected and each fraction was evaluated against the two test bacteria using 
the XTT assay. No bioactivity was detected in the fractions from the ethyl acetate extract of  
D. viscosa, despite the activity against both bacteria reported in disk diffusion assay (Table 1), and 
they were not investigated further. The butanol extract of D. viscosa yielded three fractions (18, 19 and 
20) with moderate antibacterial activity, i.e., 50%–75% reduction in bacterial growth. In contrast,  
six fractions from the hexane extract inhibited S. aureus, with this antibacterial activity resulting in 
higher than 75% reduction in bacterial activity (Figure 1). 
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(c) 
Figure 1. Preparative separation of n-hexane extract of D. viscosa using generic gradient 
and volume-based fractionation (a), percentage inhibition (b) of S. aureus (NCIMB 6571), 
percentage inhibition (c) of E. coli (NCIMB 8797), where NEG represented the negative 
control of 10% (v/v) dimethyl sulfoxide in phosphate buffer saline (DMSO/PBS) and the 
positive controls (POS) of clarithromycin (25 µg/mL) and ciprofloxacin (50 µg/mL), 
respectively (n = 2 ± SD). Fraction 42 (arrow) contained high purity, bioactive compound. 
XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) Bioassay 
results are depicted in Figure S1. 
Figure 2 shows the data from the preparative HPLC and the results of XTT assay, correlating with 
the active fractions to the corresponding peaks in the chromatogram and indicating the hydrophobic 
components of the fractions. Even if fractions with antibacterial activity were clearly evident, the 
majority of fractions enhanced bacterial viability (fractions with no inhibition), most likely due to 
additional carbon sources. 
(a) 
Figure 2. Cont. 
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(b) 
 
(c) 
Figure 2. Separation and fractionation of bioactive fraction 42 from n-hexane extract of  
D. viscosa using polarity focused gradient (a) percentage inhibition (b) of S. aureus 
(NCIMB 6571), percentage inhibition (c) of E. coli (NCIMB 8797), where NEG 
represented the negative control of 10% (v/v) DMSO/PBS and POS the positive controls of 
clarithromycin (25 µg/mL) and ciprofloxacin (50 µg/mL) respectively, (n = 2 ± SD). 
Fraction 12 (arrow) contained high purity, bioactive compound. XTT Bioassay results are 
depicted in Figure S2. 
2.5. Focused Gradients-XTT Bioassay 
Nine bioactive fractions from D. viscosa were further purified using focused gradients and each of 
the separated fractions were screened by the rapid XTT assay. The five primary fractions from the 
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hexane extract from D. viscosa resulted in 22 fractions, which inhibited growth of S. aureus, and out of 
which 18 were as active as the positive control clarithromycin. 
The combination of preparative HPLC with the XTT assay enabled the rapid isolation of bioactive 
fractions from plant extracts. In addition, after purification, information on purity and physicochemical 
properties of bioactive fractions were obtained by LC/MS analysis. Data from the XTT assay (Figure 2) 
and LC/MS analysis (Figure 3) led to focusing on one compound from D. viscosa. Though this 
information alone was not sufficient for full characterization of the compound, it provided essential 
information for monitoring, purifications and obtaining higher amounts of compounds, thus avoiding 
unnecessary bioassays. 
The prime objective of these combination bioassays was to identify fractions with antibacterial 
activity. At the preliminary stages (fractions and sub-fractions level) quantification was not considered 
necessary with the reason that synergism and/or potentiation may exist between the respective 
metabolites that exist in a particular fraction, therefore, during initial screening, fractions were analysed 
on a qualitative basis. Activity was quantified when a purified bioactive metabolite was obtained. 
The antibacterial compound 1 (Figure 4) from D. viscosa found in fractions H42 and sub-fraction 12 
was purified and its structure was elucidated using the latest spectroscopic techniques including 1D 
and 2D NMR spectra (Table 2). Compound 1 was isolated as a white crystalline solid and showed single 
absorption in UV at 217.7 nm. Its molecular formula was established as C20H28O4 by its EI-MS 
molecular ion peak at m/z 332.1879 (calculated (calcd.) for C20H28O4, 332.2013). Other major peaks 
appeared at m/z 314.9 (loss of H2O) and at m/z 270.4 (loss of H2O and CO2). The 1H-NMR spectrum 
displayed signals assignable to an unsaturated decalin system as δ = 6.86 (1H, dd, J = 2.9, 4.6 Hz  
(H-3)), 1.22 (3H, s, H-17), 0.87 (3H, d, J = 6.8 Hz (H-18)) and 0.76 (3H, s, H-20). Furthermore, the 
signals of a furane moiety appeared at δ = 6.30 (1H, brs, H-14), 7.38 (1H, t, J = 0.8 Hz, H-16) and 7.27 
(1H, brs, H-15) respectively. In addition, the 1H-NMR spectrum showed signals at δ = 3.64 (1H, dd,  
J = 10.8 Hz, 5.1 Hz (H-6)), which was assigned to Carbon 6 in the structure. 1H-1H COSY (Correlation 
Spectroscopy) experiments confirmed the C-6 proton by vicinal coupling cross peaks to both 
methylene protons of C-7. 13C-NMR spectrum revealed twenty carbon signals including six olefinic 
carbons at δC 143.2 (C-15), 111.1 (C-14), 141.9 (C-4), 140.6 (C-3), 139 (C-16) and 125.9 (C-13)  
while the acid carbonyl carbon (C-18) resonated downfield at δC 174.1. In the DEPT (Distortionless 
Enhancement by Polarization Transfer) experiment among 20 carbons, three methyl, five methylene, 
seven methine and five quaternary carbons were distinguished. Further correlations in structure  
were made through HSQC (Heteronuclear Single Quantum Coherence) and HMBC (Heteronuclear 
Multiple Bond Correlation) experiments (Table 2). The spectral data was in complete agreement with  
6β-hydroxy-15,16-epoxy-5β, 8β, 9β, 10α-cleroda-3, 13(16), 14-trien-18-oic acid, the known compound 
in literature [14]. 
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Figure 3. (a) Separation (photodiode array detector (PDA) chromatogram) of crude hexane 
D. viscosa extract by reversed phase HPLC; (b) Separation (MS chromatogram) of  
crude hexane D. viscosa extract by reversed phase HPLC; (c) bioactive fraction 42  
(PDA chromatogram) from generic preparative separation; (d) bioactive fraction 42  
(MS chromatogram) from generic preparative separation; (e) bioactive fraction 12  
(PDA chromatogram) from polarity focused separation; (f) bioactive fraction 12  
(MS chromatogram) from polarity focused separation. 
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Figure 4. Chemical structure of compound 1 from D. viscosa. 
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Table 2. 13C- and 1H-NMR spectral data (methanol-d4) and 1H/13C correlations of compound 1. 
C. 
No 
13C-NMR 
(δ) 
Multiplicity 
DEPT 
1H-NMR (δ) 1H/13C (HMBC) Connectivity 
1 17.5 CH2 α1.75 (m) β1.65 (m) H-3 (6.86) 
2 27.4 CH2 2.33 (m) H-3 (6.86), H-10 (1.40) 
3 140.6 CH 6.86 (dd, 2.9, 4.6) H-2 (2.33), Hα-1 (1.75), Hβ-1 (1.65) 
4 141.9 C – H-3 (6.86), H-6 (3.64), H-17 (1.22) 
5 45.1 C – H-3 (6.86), H-17 (1.22) 
6 75.2 CH 3.64 (dd, 5.1, 10.8) H-17 (1.22) 
7 36.4 CH2 1.60 (m) – 
8 34.4 CH 1.76 (m) H-18 (0.87), H-19 (0.76) 
9 39.3 C – H-18 (0.87) 
10 46.2 CH 1.40 (bd, 12.0) H-19 (0.76) 
11 39.0 CH2 1.61 (m) H-10 (1.40), H-20 (0.76) 
12 18.0 CH2 2.30 (m) H-19 (0.76) 
13 125.9 C – H-12 (2.30), H-14 (6.30), H-15 (7.38), H-16 (7.27) 
14 111.1 CH 6.30 (bs) H-15 (7.38), H-16 (7.27) 
15 143.2 CH 7.38 (t, 1.8) H-14 (6.30), H-16 (7.27) 
16 139.0 CH 7.27 (bs) H-12 (2.30), H-14 (6.30), H-15 (7.38) 
17 15.2 CH3 0.87 (d, 6.8) – 
18  174.1 C – – 
19 16.1 CH3 1.22 (s) H-6 (3.64) 
20 17.4 CH3 0.76 (s) – 
2.6. MIC (Minimum Inhibitory Concentration) and MBC (Minimum Bactericidal Concentration) of 
Compound 1 
The antibacterial activity of the compound 1 was quantified by evaluating the MIC (minimum 
inhibitory concentration) and MBC (minimum bactericidal concentration) against S. aureus  
(NCIMB 6571) and E. coli (NCIMB 8797). The results indicated a higher activity against S. aureus 
compared to E. coli, thereby suggesting it to be more effective against Gram-positive bacteria (Table 3 
and Figure 5). The compound was crystalline, white coloured and soluble in 10% (v/v) DMSO in PBS 
solution and, hence, no color interference was reported with the XTT assay. 
Table 3. MIC (minimum inhibitory concentration) and MBC (minimum bactericidal 
concentration) of compound 1 isolated from D. viscosa against S. aureus and E. coli. 
Bacterial Susceptibility Assays 
Compound 1 Clarithromycin Ciprofloxacin 
S. aureus E. coli S. aureus E. coli S. aureus E. coli
MIC (μg/mL) 64 128 25 – – 25 
MBC (μg/mL) 128 256 50 – – 50 
10% (v/v) DMSO in PBS served as negative control. 
A few Clerodane furanolactones and diterpenoid derivatives were previously identified in the 
liverwort Scapania nemorae [15], Solidago spp. [16] and in Aristeguetia spp. [17]. However, to the 
best of our knowledge, this is the first report on its antibacterial activity. Previously, five clerodane 
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diterpenoids isolated from Pulicaria wightiana showed antibacterial activity against Bacillus subtilis, 
B. sphaericus, S. aureus, Klebsiella aerogenes and Chromobacterium violaceum [18]. The results 
obtained from the bio-guided isolation of furanyl clerodanoic acid in D. viscosa, as well as the 
antimicrobial activity of hautriwaic acid, a D. viscosa component, reported to be active against  
B. subtilis, S. aureus and E. coli [8], support the possible use of this plant for the treatment of infectious 
diseases in the traditional systems of medicines. The application of the XTT bioassay in identification of 
bioactive metabolite and quantification of its antibacterial activity using standard test bacteria provides 
an approach that may be utilized in similar kinds of experiments. Since, in case of plant extracts, the 
commonly utilized assays (agar well diffusion and disk diffusion assays) that only highlight the 
antimicrobial activity of extracts or their fractions do not demonstrate the actual potential of that 
particular plant, more detailed standardized assays are essential. Moreover, the potential of isolated 
compounds can be easily quantified through MIC assays using the XTT bioassay-based approach. 
 
Figure 5. MICs of compound 1 (in yellow rectangle) isolated from D. viscosa against  
S. aureus (a) and E. coli (b). 
The isolated compound belongs to isoprenoids that are known to possess antimicrobial activity.  
In general, Gram-positive bacteria are more susceptible to these compounds, as confirmed by our 
results. Putative mechanisms of action may include cell membrane disruption, alteration in the cell 
membrane fluidity and permeability, increased susceptibility to antibiotics, and disturbances in the 
respiration chain due to modification of membrane-bound protein localization [19]. Moreover, isoprenoids 
may also be considered for adjuvant therapy with conventional antimicrobials, in order to reduce, delay 
or impair antibiotic resistance. Studies on antibiotic activity of clerodane type diterpenoid on other 
microorganisms are still in progress, and further investigations on its possible mechanism(s) of action 
will be planned and designed. 
3. Experimental Section 
3.1. Chemicals 
Dichloromethane, n-hexane, ethyl acetate and n-butanol were obtained from Merck (Darmstadt, 
Germany). Acetonitrile and methanol (HPLC grade) were obtained from Rathburn (Walkerburn, 
Scotland). Trifluoroacetic acid (TFA) and dimethyl sulfoxide (DMSO) were from Fisher 
(Loughborough, UK). Milli-Q system (Millipore, Watford, UK) was used for water purification. XTT 
sodium salt, menadione sodium bisulfite (2-methyl-1,4-naphthoquinone sodium bisulfite), ciprofloxacin 
and clarithromycin were from Sigma (Poole, UK). Nutrient broth and agar, Mueller-Hinton agar and 
phosphate buffered saline (PBS) were from Oxoid (Fisher, Loughborough, UK). 
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3.2. Bacterial Strains 
Preliminary screening and XTT bioassays were carried using E. coli (NCIMB 8797) and S. aureus 
(NCIMB 6571) obtained from the National Collection of Industrial, Marine and Food Bacteria 
(NCIMB; Aberdeen, UK). 
3.3. Plant Material and Extraction Procedures 
Dodonaea viscosa (L.) Jaeq. belongs to the Sapindaceae family. The aerial parts of the plant (Figure 6) 
were collected from Kohat, Khyber Pakhtoonkhwa (formerly North West Frontier Province; (NWFP)) 
(Latitude 33°19′59′′ and Longitude 71°10′0′′) Pakistan, in September 2007. A specimen was matched 
for confirmation of identity with the reference voucher number 592, preserved in the Herbarium of 
Pakistan (Quaid-i-Azam University, Islamabad, Pakistan). Shade-dried aerial parts (leaves and stems 
weighing 9 kg) of D. viscosa were ground to a fine powder and extracted with ethanol (80% v/v). The 
pulverized material was filtered using Whatman No. 1 (460 × 570 mm; approximately 11 µm pore 
size) in a percolator. Temperature during processing was maintained below 30 °C. Three portions of 
the percolate were collected at intervals of 96 h finally resulting in 11 L of extract. The ethanol was 
evaporated using a rotary evaporator (Buchi, Flawil, Switzerland) to give 2.5 L of crude extract. Crude 
aqueous fraction was sequentially partitioned with n-hexane (3 × 1 L), dichloromethane (3 × 1 L), 
ethyl acetate (3 × 1 L) and n-butanol (3 × 1 L) and combined extractions were dried by rotary 
evaporation [20]. 
 
Figure 6. Dodonaea viscosa (L.) Jaeq., Florida Hopbush, Hopbush, Varnish plant, 
Ghwaraskay (Pushto), Vilayeti-mehndi (Hindi; Urdu). 
3.4. Chemical Characterization 
3.4.1. Preparative HPLC 
Preparative HPLC was performed using a Biotage Parallex Flex (Biotage, Cardiff, UK) where Flex 
V3 software was used for instrument control and data acquisition. Separations were performed on a 
Hyperprep HS C18 column (10 mm I.D. (internal diameter) × 150 mm long; 8 µm particle size; 
Thermo scientific, Cheshire, UK) with a pre column (KR 100-13 C18-10 CP; Hichrom Ltd., Berkshire, 
UK). Mobile phase included Milli-Q water (A), and methanol (B). The crude samples were separated 
using a gradient increasing from 10% to 100% B over 50 min at a flow rate of 10 mL/min. The 
concentration of crude fractions was 0.2 g/mL, and each injection volume was 0.25 mL. Eluent was 
monitored at 220 and 254 nm and fractionation was volume-based, collecting 9 mL fractions into deep 
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well microtitre plates (24 × 10 mL; Whatman, Kent, UK). The butanol extract of D. viscosa had three 
fractions (18, 19 and 20) with moderate antibacterial activity (50%–75% reduction in bacterial 
growth), while six fractions from the hexane extract inhibited only S. aureus (>75% reduction in 
bacterial activity) (Figure 2 and Table 2). Using the data available on the percentage of methanol 
eluting the bioactive fractions, shorter (30 min) focused gradients were selected for further purification 
of all the primary bioactive fractions, as summarized for each fraction in Table 4. 
Table 4. Bioactive fractions from extracts of D. viscosa separated by preparative HPLC. 
Sample—Fraction (mg Dry Weight) Percentage Methanol Focused Gradient 
D. viscosa—B18 a (1.0) 42 
25%–55% methanol D. viscosa—B19 (2.2) 43 
D. viscosa—B20 (5.9) 45 
D. viscosa—H42 b (1.9) 83 
80%–100% 
D. viscosa—H44 (2.9) 86 
D. viscosa—H47 (1.6) 91 
D. viscosa—H50 (1.1) 97 
D. viscosa—H51 (1.0) 98 
D. viscosa—H52 (1.6) 100 80%–100% and hold for 10 min
a Fractions from crude butanol extracts (B); b Fractions from crude hexane (H) extract. 
Focused Separation of Bioactive Fractions 
Fractions from the generic separations that exhibited antibacterial activity were dried, weighed and 
re-dissolved in 0.5 mL methanol. These were further purified using polarity focused gradients based on 
the proportion of methanol in which they were eluted during the generic gradient (Table 2). Column 
and solvents were as described in Section 3.4.1 with an injection volume of 0.25 mL. Fraction 
collection was based on volume (9 mL fraction). 
A total of nine bioactive fractions from D. viscosa were further purified using focused gradients 
over 30 min. Each separation resulted in 35 fractions which were screened by the rapid XTT assay 
(Figure 2). The five primary fractions from the hexane extract from D. viscosa resulted in 22 fractions 
(Table 5) which inhibited S. aureus, out of 18 as active as to the positive control clarithromycin, 
indicating the potential of this plant as a source of new drugs or drug scaffolds. Slight or no activity 
was observed in E. coli (Figure 2). 
Table 5. Summary of bioactive sub-fractions from focused preparative HPLC runs of 
fractions from D. viscosa hexane fraction. 
Sample—Primary Fraction Sub-Fraction 
D. viscosa—H42 12, 14, 21–24, 29, 30
D. viscosa—H44 15, 17 
D. viscosa—H50 25–27 
D. viscosa—H51 27–30 
D. viscosa—H52 21, 23, 24, 37, 38 
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3.4.2. Analytical HPLC 
The HPLC system consisted of a Waters Alliance 2695 with a 2996 photodiode array detector 
(PDA) and a ZQ 2000 mass spectrometer (Elstree, Hertfordshire, UK). A Sunfire C18 column (Length 
150 mm × 2.1 mm I.D., particle size 5 µm) which was maintained at 40 °C was used for separation. 
Mobile phase was Milli-Q water (A) and acetonitrile (B) both containing 0.05% TFA. A gradient 
increasing from 5% to 100% B over 30 min at a flow rate of 0.3 mL/min was used for separation of 
samples (10 µL). Eluent was monitored from 210 to 400 nm with a resolution 1.2 nm and by positive 
ion electrospray (ESI+) in series, scanning from m/z 100 to 1600 with a scan time of 2 s and inter-scan 
delay of 0.1 s. Ion source parameters: Sprayer voltage, 3.07 KV; cone voltage, 40 V; desolvation 
temperature, 300 °C; source temperature, 100 °C. Instrument control, data acquisition and processing were 
done using MassLynx v4.1 (Waters, Elstree, Hertfordshire, UK). The active component in the n-hexane 
extract of D. viscosa was found in H42 (Figure 1) and sub-fraction 12 (Figure 2), where the relative purity 
(PDA—210 to 400 nm) achieved was >90% (Figure 3). 
3.4.3. Physical and Spectral Data for Compound 1 
6β-hydroxy-15,16-epoxy-5β, 8β, 9β, 10α-cleroda-3, 13(16), 14-trien-18-oic acid: 
Crystalline solid (20 mg): UV (λmax, MeOH) = 217.7 nm. HR-EIMS m/z = 332.1879 (calcd. for 
C20H28O4, 332.2013). The 1H-NMR (400 MHz) and 13C-NMR (100 MHz) were recorded in MeOD-d4 on 
a BRUKER Ultrashield 400 (Bruker UK Limited, Coventry, UK) (Table 2). 
3.5. Antibacterial Activity 
3.5.1. Preliminary Antibacterial Screening 
Crude extracts (16.7 mg/mL) were re-suspended in methanol and sterilized using Millex,  
33 mm filter (0.22 µm pore size; Millipore, Watford, UK). Aliquots (6 µL) were applied to sterile 
disks (6 mm diameter punched from Whatman No. 1 filters). Negative control disks had same  
volume of methanol on each disk. Ciprofloxacin (10 µg/disk) and clarithromycin (15 µg/disk)  
served as the positive controls for E. coli NCIMB 8797 and S. aureus NCIMB 6571, respectively.  
The bacteria were kept on nutrient agar and fresh standardized inocula, turbidity equivalent to  
0.5 McFarland (≈1.5 × 108 CFU/mL) [21], were used for each experiment. Disks containing the crude 
extracts, negative control disks (methanol) and positive controls were aseptically placed on the seeded 
plates. Prior to overnight incubation at 37 °C, seeded plates with disks were kept in inverted position in 
refrigerator for 2 h to allow adequate diffusion of extracts. All the tests were performed in triplicate. 
3.5.2. XTT Bioassay 
XTT solution (1 mg/mL) in PBS was prepared and sterilized using Millex, 33 mm filter (0.22 µm 
pore size; Millipore, Watford, UK) and stored at −80 °C in cryotubes (Cole-Parmer, London, UK)  
until use. Menadione (173 μg/mL) in acetone was prepared fresh before to every assay. XTT aliquots 
were thawed at room temperature and, then, menadione was added to XTT (1:12). From each fraction 
collected during prep-HPLC, an aliquot (300 µL) was placed in glass vials (2 mL; Alltech, Carnforth, 
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UK) and dried overnight in a laminar flow cabinet and re-suspended in 10% v/v DMSO/PBS (400 µL) [22]. 
Samples (100 µL) were transferred into the wells of 96-well flat bottom microtiter plates (Sterilin, 
Aberbargoed, UK). E. coli NCIMB 8797 and S. aureus NCIMB 6571 inocula were prepared as 
mentioned earlier. Inoculum (100 µL) of each test bacteria was added to each of the test well, into 
negative control (DMSO/PBS) and positive control (ciprofloxacin for E. coli, and clarithromycin for  
S. aureus) wells. XTT/menadione mixture (18 µL) was added to each test well and plates were gently 
shaken. Absorbance at 490 nm was recorded using a BioTek microplate reader (Fisher, Loughborough, 
UK) at the start of the test and after overnight incubation at 37 °C. All tests were performed in 
duplicate. Percent increase in absorbance (X) was calculated using formula 1, where AtN and At0 
represented mean absorbance values after 24 h incubation and at the start of test, respectively. 
Similarly, percentage increase in negative control (N) was also calculated using Equation (1). Percent 
reduction (R) in cell metabolism was calculated using Equation (2), where XN and TN represented 
percent increase in absorbance of test material and negative control, respectively, at time (N) which 
was standardized at 24 h. 
XtN = AtN − At0/At0 × 100 (1)
R = 100 − ((XN/TN) × 100) (2)
Fractions were considered to have an antibacterial effect when they gave a mean (n = 2) reduction 
in the XTT colorimetric bioassay of ≥50% (threshold level for antibacterial activity), and <50% value 
was termed to have slight or no antibacterial activity [13,23]. 
Determination of Minimum Inhibitory Concentration (MIC) of Purified Compound 
MIC is defined as the lowest antimicrobial concentration that completely inhibits visible bacterial 
growth, as detected visually or via an automated or semiautomated method. One hundred µL of 
purified compound solution (256 µg/mL) in DMSO/PBS was transferred aseptically to the microtiter 
plates and, sequentially, half diluted in sterile solution of DMSO/PBS such that final dilution of  
2 µg/mL was achieved. Then 100 µL of standardized inoculum (≈1.5 × 108 CFU/mL) was added to each 
of the test wells and into negative control (DMSO/PBS) and positive control (ciprofloxacin for E. coli 
and clarithromycin for S. aureus) containing wells. Then, to each test well, 18 µL of XTT/menadione 
reagent were added and plates were gently shaken. Absorbance at 490 nm was recorded using 
microplate reader at the start of the test and, then, after 24 h of incubation at 37 °C. The tests were run 
in duplicate. The wells having no visible bacterial growth, detected visually and having no change in 
absorbance before and after 24 h of application of test defined the MIC of the compound. 
3.5.3. Determination of Minimum Bactericidal Concentration (MBC) of Purified Compound 
The MBC was defined as the concentration of the antimicrobial agent that results in the 99.9% 
reduction in CFU/mL, compared with the organism concentration in the original inocula. The plates 
used for the evaluation of MIC were utilized such that, after 24 h incubation, the wells that were 
visibly clear and showed no metabolic activity of bacteria, ascertained from the absorbance and % 
reduction in bacterial population readings (evaluated using formulas given in Section 3.5.2.), were 
selected and 50 µL aliquots from each well were spread separately on the entire surfaces of sterile 
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nutrient agar plates with the help of sterile glass spreader, and incubated in inverted position overnight 
at 37 °C. The tests were run in duplicate. The aliquots of wells that gave no growth defined the MBC 
of the compound. 
4. Conclusions 
The combination of automated preparative HPLC with simple generic gradients followed by 
focused gradients combined with the XTT bioassay led to the identification of sub-fractions with slight 
antibacterial activity. This approach resulted in isolation of a clerodane type diterpenoid, 6β-hydroxy-
15,16-epoxy-5β, 8β, 9β, 10α-celoda-3, 13(16), 14-trien-18-oic acid from D. viscosa, with MIC of  
64 and 128 µg/mL, and MBC of 64 and 256 µg/mL against S. aureus and E. coli, respectively. This 
supports the use of D. viscosa as antibacterial remedy in traditional systems of healing. Further 
evaluations of antibacterial spectrum are required. Although only one compound was isolated during 
this study, there were clearly several bioactive compounds which require further investigation. Moreover, 
the approach applied in identification and standardization of active metabolite can be capitalized in 
similar research. 
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